Clinical Trials
3 trialsNCT00379080 2017-04-07
Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00667394 2015-11-05
Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00904852 2009-05-20
Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme
Millennium Pharmaceuticals, Inc.
Phase 1 Withdrawn